Refractory Solid Tumors Clinical Trial
Official title:
A Phase I/II Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
This IND-exempt Phase I trial will establish the recommended Phase II (RP2D) dose of eribulin in combination with fixed doses of oral irinotecan in adolescents and young adults with relapsed or refractory solid tumors. Eribulin will be administered intravenously on days 1 and 8 of a 21-day cycle, while irinotecan will be administered orally on days 1-5. Patients will be assigned an eribulin dose level at the time of enrollment using a 3+3 Phase I design, and there will be no intrapatient dose escalation. Once the RP2D has been established, there will be up to 10 patients enrolled in a dose expansion cohort. In absence of disease progression or toxicity, subjects may receive up to 17 cycles of therapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00404508 -
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT02450136 -
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT00759928 -
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06150365 -
Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT01247168 -
An Open-Label, Dose-Escalation Study of AZD2461
|
Phase 1 | |
| Completed |
NCT00665990 -
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
|
Phase 1 | |
| Completed |
NCT02691793 -
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
|
Phase 4 | |
| Completed |
NCT02450149 -
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02691767 -
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
|
N/A | |
| Terminated |
NCT00664586 -
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05811975 -
KSX01-TCRT Injection Project in Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT03810742 -
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03096340 -
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02450123 -
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02383368 -
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
|
Phase 1 | |
| Completed |
NCT00394446 -
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03052205 -
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT02482441 -
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
|
Phase 1 | |
| Recruiting |
NCT03739827 -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|
||
| Recruiting |
NCT05150457 -
Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
|
Phase 1 |